0 95

Cited 7 times in

In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates

DC FieldValueLanguage
dc.contributor.author용동은-
dc.contributor.author이경원-
dc.contributor.author이혁민-
dc.contributor.author정석훈-
dc.contributor.author홍덕진-
dc.date.accessioned2017-10-26T07:33:06Z-
dc.date.available2017-10-26T07:33:06Z-
dc.date.issued2016-
dc.identifier.issn0732-8893-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/152181-
dc.description.abstractIncreased use of colistin in a clinical setting had resulted in the emergence of colistin-resistant (CoR) Acinetobacter baumannii. Combination therapy has been studied as a new approach to treat infections caused by A. baumannii. Here, we investigated the in vitro antimicrobial synergistic activities of several antimicrobial agent combinations against CoR A. baumannii. A total of 41 non-duplicate clinical isolates of CoR A. baumannii from a tertiary care hospital in Korea were prospectively collected from April 2012 to December 2014. As a control group, 41 carbapenem-resistant but colistin-susceptible (CoS) A. baumannii strains were also evaluated. Minimum inhibitory concentrations (MICs) of antimicrobial agents were determined by Etest in triplicate, and in vitro synergy tests were performed by the Etest MIC:MIC ratio method. Synergistic activity was determined as the sum of each antimicrobial agent's fractional inhibitory concentration evaluated (ΣFIC): synergy, ≤0.5; indifference, >0.5-4; and antagonism, >4. Synergistic activities were more frequently observed in the CoR group than the CoS group for combinations of colistin-rifampicin (80.5% vs. 14.6%, P< 0.0001), colistin-meropenem (85.4% vs. 4.9%, P< 0.0001), and colistin-imipenem (46.3% vs. 2.4%, P< 0.0001). Combination with rifampicin or meropenem lowered colistin MICs against CoR A. baumannii clinical isolates to the susceptible range (≤ 2 μg/mL) more frequently (61.0%, 25/41, both) than combination with imipenem (29.3%, 12/41). Clinical trials are needed to prove the in vivo efficacy of those antimicrobial combinations that exhibited significant in vitro antimicrobial synergistic effects against CoR A. baumannii.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier Biomedical-
dc.relation.isPartOfDiagnostic Microbiology and Infectious Disease-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAcinetobacter Infections/microbiology*-
dc.subject.MESHAcinetobacter baumannii/drug effects*-
dc.subject.MESHAcinetobacter baumannii/isolation & purification-
dc.subject.MESHAnti-Bacterial Agents/pharmacology*-
dc.subject.MESHCarbapenems/pharmacology*-
dc.subject.MESHColistin/pharmacology*-
dc.subject.MESHDrug Resistance, Bacterial-
dc.subject.MESHDrug Synergism*-
dc.subject.MESHHumans-
dc.subject.MESHMicrobial Sensitivity Tests-
dc.subject.MESHProspective Studies-
dc.subject.MESHRepublic of Korea-
dc.subject.MESHRifampin/pharmacology*-
dc.subject.MESHTertiary Care Centers-
dc.titleIn vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates-
dc.typeArticle-
dc.publisher.locationUnited States-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Laboratory Medicine-
dc.contributor.googleauthorDuck Jin Hong-
dc.contributor.googleauthorJung Ok Kim-
dc.contributor.googleauthorHyukmin Lee-
dc.contributor.googleauthorEun-Jeong Yoon-
dc.contributor.googleauthorSeokHoon Jeong-
dc.contributor.googleauthorDongeun Yong-
dc.contributor.googleauthorKyungwon Lee-
dc.identifier.doi10.1016/j.diagmicrobio.2016.07.017-
dc.contributor.localIdA02649-
dc.contributor.localIdA03286-
dc.contributor.localIdA03619-
dc.contributor.localIdA04389-
dc.contributor.localIdA02423-
dc.relation.journalcodeJ00731-
dc.identifier.pmid27475960-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0732889316302115?via%3Dihub-
dc.subject.keywordAcinetobacter baumannnii-
dc.subject.keywordColistin-
dc.subject.keywordCombination-
dc.subject.keywordMeropenem-
dc.subject.keywordRifampicin-
dc.subject.keywordSynergism-
dc.contributor.alternativeNameYong, Dong Eun-
dc.contributor.alternativeNameLee, Kyung Won-
dc.contributor.alternativeNameLee, Hyuk Min-
dc.contributor.alternativeNameJeong, Seok Hoon-
dc.contributor.alternativeNameHong, Duck Jin-
dc.contributor.affiliatedAuthorLee, Kyung Won-
dc.contributor.affiliatedAuthorLee, Hyuk Min-
dc.contributor.affiliatedAuthorJeong, Seok Hoon-
dc.contributor.affiliatedAuthorHong, Duck Jin-
dc.contributor.affiliatedAuthorYong, Dong Eun-
dc.citation.volume86-
dc.citation.number2-
dc.citation.startPage184-
dc.citation.endPage189-
dc.identifier.bibliographicCitationDiagnostic Microbiology and Infectious Disease, Vol.86(2) : 184-189, 2016-
dc.date.modified2017-10-24-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.